NCT04939090 2026-03-04
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
Clinical Trials
19 trialsNCT06200181 2026-02-13
Effect of Olanzapine on Opioid Craving and Misuse Among Patients Receiving Opioids for Cancer-related Pain: A Pilot Double-Blind, Randomized Control Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
NCT07035821 2025-06-25
Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy
Shanghai Children's Medical Center
Phase 3 Not yet recruiting
NCT04503668 2025-06-18
Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting in Gynecologic Oncology Patients
University of Michigan Rogel Cancer Center
Phase 3 Terminated
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT06588413 2024-11-22
FONDO-LOW
Augusta University
Phase 3 Recruiting
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT05243251 2024-10-03
Olanzapine Anorexia Cachexia
Cairo University
Phase 3 Completed
NCT06517199 2024-07-24
Olanzapine for Cancer Related Anorexia-cachexia Syndrome
Mahidol University
Phase 3 Recruiting
NCT06500234 2024-07-15
Nutrition Impact on Immunotherapy of Cancer
Qingdao Central Hospital
Phase 3 Recruiting
NCT05403580 2024-05-06
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
Mayo Clinic
Phase 3 Withdrawn
NCT06338683 2024-03-29
Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer
Qinghai Red Cross Hospital
Phase 3 Recruiting
NCT05244577 2023-02-06
Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer
Sun Yat-sen University
Phase 3 Unknown
NCT04536558 2020-09-02
OFFER
Sun Yat-sen University
Phase 3 Unknown
NCT02861859 2020-02-26
Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
Ottawa Hospital Research Institute
Phase 3 Completed
NCT02635984 2018-08-20
FOND-O
Augusta University
Phase 3 Completed
NCT00124930 2012-01-19
Study Comparing Olanzapine With Haloperidol for the Relief of Nausea and Vomiting in Patients With Advanced Cancer
AHS Cancer Control Alberta
Phase 3 Terminated